AmerStem is a privately held plant biotechnology company headquartered and operating a state-of-the-art indoor vertical cultivation facility in Camarillo, California, located along the Highway 101 corridor in Ventura County. The company positions itself as a leading green biotechnology company focused on the sustainable production of plant-derived saponins using indoor controlled-environment agriculture rather than wild harvesting of natural tree populations.

AmerStem’s founding scientific rationale addresses a well-documented supply chain vulnerability in the global vaccine adjuvant market: QS-21 and related Quillaja saponaria-derived saponin immunoadjuvants — critical components of adjuvant systems used in vaccines for shingles, malaria, HIV, COVID-19, and other indications — are currently sourced exclusively from the bark of Quillaja saponaria trees native to Chile and Argentina. These trees are under threat from overharvesting, deforestation, and habitat loss, creating a long-term supply security concern for vaccine manufacturers globally. AmerStem’s proprietary AeroStemix plant cell culture and vertical farming technology platform is designed to produce equivalent saponin compounds at commercial scale without requiring any harvesting of wild Quillaja trees.

The company’s multidisciplinary scientific team brings expertise in molecular analytics, plant physiology, and plant cultivation, and its Camarillo facility houses both laboratory and commercial-scale indoor cultivation infrastructure established in 2026. AmerStem’s long-term vision encompasses broader applications of its AeroStemix platform across sustainable agriculture, forestry biomass generation, and pharmaceutical phytoactive production.

Key Products and Services

Proprietary Technology Platform

• AeroStemix™ — a proprietary plant cell culture and indoor vertical farming technology platform developed to produce saponin immunoadjuvants and other plant-derived phytoactives at commercial scale under controlled, indoor conditions without reliance on adult tree cultivation or wild harvesting
• The platform is designed to enable reproducible, scalable, and season-independent production of plant-derived compounds, addressing the supply variability and environmental impact inherent in conventional wild-harvest-based saponin sourcing

Saponin Immunoadjuvant Production

• QS-21 — a purified saponin immunoadjuvant derived from Quillaja saponaria bark, widely used in AS01B and AS01E adjuvant systems incorporated into licensed vaccines including Shingrix (shingles) and Mosquirix (malaria RTS,S), and in clinical development for a wide range of next-generation vaccine programmes
• Quillaja saponin immunoadjuvants — additional Quillaja-derived saponin fractions for use as vaccine adjuvants in development and commercial vaccine programmes
• Plant-derived saponins for pharmaceutical and nutraceutical applications

Saponin Application Markets

• Vaccine adjuvants — primary commercial focus; saponin immunoadjuvants for use in human vaccine development and manufacturing
• Organic surface disinfectants — saponins with demonstrated antiviral, antifungal, and antibacterial surface disinfection properties
• Agriculture — plant saponins as natural pesticide alternatives and crop protection agents
• Animal feed additives — saponins as growth performance and gut health modulators in livestock and aquaculture
• Personal care and cosmetics — saponins as natural surfactants in personal care formulations
• Pharmaceuticals — phytoactive saponin compounds with pharmacological properties for pharmaceutical development applications

Industry Positioning

AmerStem occupies a strategically significant niche in the vaccine supply chain as one of a small number of companies globally attempting to develop a sustainable, tree-independent manufacturing route for QS-21 and related Quillaja saponin adjuvants. The strategic importance of this problem is substantial: QS-21 is a non-negotiable component of the AS01 adjuvant system used in GlaxoSmithKline’s Shingrix vaccine — the world’s most commercially successful vaccine by revenue — and is incorporated into a growing number of next-generation vaccine candidates in development, meaning that long-term supply security of QS-21 is a material concern for multiple global vaccine manufacturers simultaneously. The conventional supply chain’s dependence on a single tree species native to a geographically constrained habitat, subject to environmental and regulatory pressures, creates a structural vulnerability that plant cell culture and vertical farming-based production routes are specifically designed to address. AmerStem’s AeroStemix platform, if it achieves commercial-scale production at the quality and purity specifications required for pharmaceutical-grade immunoadjuvant use, would represent a meaningful contribution to vaccine supply chain resilience. As of 2026, the company has established its Camarillo commercial production facility, though its development stage, regulatory status, and customer relationships are not yet publicly disclosed.